Released Nov 11, 2022, after the close
10-Q filed Nov 14, 2022, 45 days after period end · 0001390478-22-000028
Q3 2022 · 10-Q
Revenue$0.00$0.00 — vs Q3 2021no prior Q2 2022 on file
Net Income-$7.02M-$7.02M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.34-$0.34 N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$7,146,000N/M
Operating Cash Flowderived-$5,746,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — |
| Net Income | -$7.02M | -$7.09M | -$4.47M | -$4.20M |
| EPS Diluted | -$0.34 | -$0.45 | -$0.53 | -$2.68 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR